About Us

About Us

Catenion is a management consulting firm devoted to helping pharmaceutical and medical products companies create more innovative and effective strategies and organizations.

We draw on our deep understanding of industry trends and company dynamics to help our clients develop actionable competitive strategies. We also address the cultural impediments to pharmaceutical innovation by helping clients create the organizational climates that foster creativity and medical breakthroughs. At the same time we also greatly improve how our clients assess the value and risk of their project and product portfolios and how they allocate resources.

We work with board directors, CEOs, business unit general managers, heads of R&D, finance, strategy, portfolio management, business development and other executives who want to improve the performance of the organization. We are able to do so because of three differentiators:

Science-Driven Strategy

We focus on science-driven strategy: we answer key questions through comprehensive multidimensional assessments conducted by our team of life science PhDs.

Experience & Relationships

We have two decades of experience and relationships globally across the biopharmaceutical industry.

Data Science

We integrate Data Science in our analyses with a team of bioinformaticians, computational biologists and data engineers.

We are equally passionate about helping our clients boost innovation and thus contributing to medical advances. We are constantly seeking entreprenurial opportunities related to our core capabilities and are willing to go at risk.

Our Values

A number of principles have shaped, and will continue to shape, our firm:

As a result, we continually perfect and re-invent our approaches and analytical methods, always go the extra mile, and are much better at delivering our services than at selling ourselves.
Catenion partners and consultants are here because they love the work they do — not to build a CV and use their experience as a stepping stone on the path to professional glory.

Meet the Team

Dr. Markus Thunecke

Senior Partner

Dr. Matthias Krings

Senior Partner

Arno Heuermann

COO, Partner/Managing Director

Christian Elze

Senior Partner

Dr. Pascal Joly

Principal

Dr. Mariana Cerdeira

Manager

Dr. Ana Rita da Costa

Manager

Dr. Simin Oz

Manager / Data Scientist

Dr. Damir Omerbasic

Manager

Dr. Bea Kaufmann

Manager

Dr. Erika Kuchen

Associate / Data Scientist

Dr. Mayur Vadhvani

Associate

Dr. Tahere Kalantary

Associate / Data Scientist

Dr. Andrea Iseppon

Associate

Dr. Ilkin Ozer

Associate

Dr. Alexander Wallroth

Associate

Duc Vu

Associate

Dr. Christopher Buccitelli

Associate / Data Scientist

Haydar Demirdizen

Senior Data Engineer

Pascal Stehling

Data Engineer

Dr. Marija Liutkute

Analyst

Dr. David Puga

Analyst

Dr. Lina Zárate

Analyst

Dr. Charles Malek

Analyst

Dr. Saren Tasciyan

Analyst / Data Scientist

Dr. Yu-Wen Hsieh

Analyst

Dr. Giulia Caglio

Analyst / Data Scientist

Jie-Ming (Jamie) Lin

Analyst

Dr. Shilpashree Mallesh

Analyst

Dr. Priyankaa Pitcheshwar

Analyst

Dr. Daniel Bauer

Analyst

Dr. Jiesi Chen

Analyst

Linda Schermeier

Researcher

Marco Serrano

Data Engineer

To be announced

Data Scientist

To be announced

Analyst

Bettina Eyermann

Office Manager

Deborah Frick

Finance Manager

Katarina Ebert

People & Talent Manager

Code of Ethics

At Catenion, integrity, ethics and transparency are very important. Therefore, we are proud to share our Code of Ethics with our clients, providers and team.
Catenion Markus Thunecke compressed

Dr. Markus Thunecke

Markus has written several Catenion Commentaries including “Risk Profiles of Corporate Portfolio Strategies” as well as “Elements of Winning Strategies in R&D”, “Recombinant Innovation Management (RIM) – How to Stimulate Breakthrough Innovation within Large R&D Organisations”, “Recombinant Portfolio Management – Recognising and Enabling Innovation”. He also co–authored “Zero Base R&D” and “The Challenge for Japan’s Pharmaceutical Top Twenty”. All of them are part of Catenion’s “Shaping Pharmaceutical Strategy” series that focuses on high-profile issues for the industry.

Markus Thunecke is a founding Senior Partner of Catenion who lives in Berlin, Germany. Markus started his consulting career in 1997 at Mercer Management Consulting before joining a strategy consulting boutique, Theron, and setting up Catenion in 2003.

Markus has helped numerous clients around the globe in the pharmaceutical and medical products industries create competitive advantage. In addition to his work on strategy, Markus specialises in developing leading–edge analytical tools and combining them with organisational development capabilities. Markus is the developer of a number of Catenion’s proprietary tools for portfolio management and risk assessment. In recent engagements, Markus has helped clients develop and realign their R&D strategies, review their discovery and development portfolios, and create organisational models that foster innovation.

Markus is a frequent speaker at conferences on R&D strategy and portfolio management.

He holds a PhD in biochemistry from the University of Heidelberg, where he generated transgenic animal models for Alzheimer’s disease. He also has three years of research experience within the CNS field at Schering AG.

Catenion Matthias Krings

Dr. Matthias Krings

Matthias Krings is a founding Partner of Catenion.

He has worked for international pharma, biotech and medtech organizations on a variety of topics. Matthias works with clients on developing corporate and R&D strategies, identifying new areas of opportunity, tailoring asset and company searches for BD&L and M&A, maximizing the value of existing assets through therapeutic expansion, and prioritizing R&D portfolios. Matthias is also resposible for the creation and delivery of bespoke client education programs in the Catenion Academy.

Before co-founding Catenion in 2003, Matthias was a consultant at Mercer Management Consulting (now Oliver Wyman) and later joined a strategy consulting boutique, Theron.

Matthias holds a diploma and a doctorate degree in Biology from the Ludwig-Maximilians University in Munich. His PhD work was supported by a scholarship from the Boehringer Ingelheim Fonds, Foundation for Basic Research in Medicine. Matthias made significant scientific contributions to the field of human evolution (Krings et al., Cell 1997: Neandertal DNA Sequences and the Origin of Modern Humans).

Matthias lives in Munich & Berlin. He enjoys cooking, gardening, watersports and traveling.

Matthias co-authored Catenion’s Commentaries “Elements of Winning Strategies in R&D” and “Recombinant Portfolio Management – Recognizing and Enabling Innovation”. They are part of Catenion’s “Shaping Pharmaceutical Strategy” series that focuses on high-profile issues for the industry.

Catenion Arno Heuermann 2

Arno Heuermann

Arno Heuermann is a founding Partner of Catenion who lives in Berlin, Germany. Arno has ten years of experience as CEO and COO. He has managed companies in Germany, France and Luxemburg.

While working on his degrees, Arno founded a technical engineering office in 1994. He continued to follow the entrepreneurial path in 1998 by founding Biopsytec GmbH, a DNA diagnostics company focused on agriculture, heading the company for more than five years as Managing Director.

In 1999, he co–founded Epigenomics AG, a public biotech company focused on DNA methylation, later remaining as an advisor and member of the firm’s Supervisory Board.

In August 2000, Arno orchestrated the founding and financing of Biopsytec Holding AG, thus merging Genious SA and the QTL AG and Biopsytec GmbH. He managed Biopsytec Holding AG for the next three years before helping launch Catenion in 2003. Since that time, he has been Catenion’s chief operating officer.

Arno holds a diploma degree in process engineering from the Technical University of Applied Sciences in Berlin. In addition, Arno attended the Berlin business school for Industrial Engineering and Management.

He is experienced in the diverse practices of patent management and has made numerous successful inventions.

Arno Heuermann is married and has two children. He is a lover of classical music, country life and horseback riding.

Catenion Christian Elze

Christian Elze

Christian Elze is a founding partner of Catenion and has been developing the company’s business in Japan since 2008. He holds a BSc from the London School of Economics and an MBA from Columbia University.

Christian is working with companies, universities and governments in the field of biomedical innovation. In his work, Christian is focusing on how emerging technologies and translational research are re-shaping the respective roles of funding agencies, investors, biopharma companies and academia in the research and development of new drugs.

Besides his consulting work, Christian frequently speaks about Emerging Technologies, Healthcare Reform, Pricing & Reimbursement,  Biomedical Innovation, as well as Translational Research at industry conferences and universities in Japan, the US and Europe.

Christian is a fluent speaker of English, French, German, Italian, Portuguese, Russian and Spanish and lives with his family in London.